Publications by authors named "Peter Connick"

Claim this Profile
O
Optical coherence tomography in secondary progressive multiple sclerosis: cross-sectional and longitudinal exploratory analysis from the MS-SMART randomised controlled trial.
Floriana De Angelis, James R Cameron, Arman Eshaghi, Richard Parker, Peter Connick

J Neurol Neurosurg Psychiatry· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brain reserve and physical disability in secondary progressive multiple sclerosis.
Nevin John, Yingtong Li, Floriana De Angelis, Jonathan Stutters, Ferran Prados Carrasco, Peter Connick

BMJ Neurol Open· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fatigue in early multiple sclerosis: MRI metrics of neuroinflammation, relapse and neurodegeneration.
Rozanna Meijboom, Peter Foley, Niall J J MacDougall, Yair Mina, Elizabeth N York, Peter Connick

Brain Commun· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patterns of brain atrophy in recently-diagnosed relapsing-remitting multiple sclerosis.
Rozanna Meijboom, Elizabeth N York, Agniete Kampaite, Mathew A Harris, Nicole White, Peter Connick

PLoS One· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic, comprehensive, evidence-based approach to identify neuroprotective interventions for motor neuron disease: using systematic reviews to inform expert consensus.
Charis Wong, Jenna M Gregory, Jing Liao, Kieren Egan, Hanna M Vesterinen, Peter Connick

BMJ Open· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Network analysis characterizes key associations between subjective fatigue and specific depressive symptoms in early relapsing-remitting multiple sclerosis.
Yuan-Ting Chang, Patrick K A Kearns, Alan Carson, David C Gillespie, Rozanna Meijboom, Peter Connick

Mult Scler Relat Disord· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Patient Health Questionnaire (PHQ-9) as a tool to screen for depression in people with multiple sclerosis: a cross-sectional validation study.
Emily Beswick, Suzanne Quigley, Pamela Macdonald, Sarah Patrick, Shuna Colville, Peter Connick

BMC Psychol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Remyelination varies between and within lesions in multiple sclerosis following bexarotene.
J William L Brown, Ferran Prados, Daniel R Altmann, Baris Kanber, Jonathan Stutters, Peter Connick

Ann Clin Transl Neurol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The influence of disease-modifying therapy on hidden disability burden in people with newly diagnosed relapsing-remitting multiple sclerosis.
Stella A Glasmacher, Patrick Ka Kearns, Zackary Hassan, Peter Connick, Simone Tauber

Mult Scler Relat Disord· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Fluoxetine, Riluzole and Amiloride in treating neuropathic pain associated with secondary progressive multiple sclerosis. Pre-specified analysis of the MS-SMART double-blind randomised placebo-controlled trial.
Peter Foley, Richard A Parker, Floriana de Angelis, Peter Connick, Siddharthan Chandran

Mult Scler Relat Disord· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal retinal imaging study of newly diagnosed relapsing-remitting multiple sclerosis in Scottish population: baseline and 12 months follow-up profile of FutureMS retinal imaging cohort.
Yingdi Chen, Juan Larraz, Michael Wong, Patrick Kearns, Fraser Brown, Peter Connick

BMJ Open Ophthalmol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FutureMS cohort profile: a Scottish multicentre inception cohort study of relapsing-remitting multiple sclerosis.
Patrick K A Kearns, Sarah J Martin, Jessie Chang, Rozanna Meijboom, Elizabeth N York, Peter Connick

BMJ Open· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale and design of the brain magnetic resonance imaging protocol for FutureMS: a longitudinal multi-centre study of newly diagnosed patients with relapsing-remitting multiple sclerosis in Scotland.
Rozanna Meijboom, Stewart J Wiseman, Elizabeth N York, Mark E Bastin, Maria Del C Valdés Hernández, Peter Connick

Wellcome Open Res· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
iPSC-derived myelinoids to study myelin biology of humans.
Owen G James, Bhuvaneish T Selvaraj, Dario Magnani, Karen Burr, Peter Connick

Dev Cell· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MRI-derived g-ratio and lesion severity in newly diagnosed multiple sclerosis.
Elizabeth N York, Sarah-Jane Martin, Rozanna Meijboom, Michael J Thrippleton, Mark E Bastin, Peter Connick

Brain Commun· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study.
J William L Brown, Nick G Cunniffe, Ferran Prados, Baris Kanber, Joanne L Jones, Peter Connick

Lancet Neurol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
iPSC-derived myelinoids to study myelin biology of humans.
Owen G James, Bhuvaneish T Selvaraj, Dario Magnani, Karen Burr, Peter Connick

Dev Cell· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic review of prediction models in relapsing remitting multiple sclerosis.
Fraser S Brown, Stella A Glasmacher, Patrick K A Kearns, Niall MacDougall, David Hunt, Peter Connick

PLoS One· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MS-SMART study: systematic sampling bias concerns - Authors' reply.
Jeremy Chataway, Floriana De Angelis, Peter Connick, Richard A Parker, Anisha Doshi

Lancet Neurol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.
Jeremy Chataway, Floriana De Angelis, Peter Connick, Richard A Parker, Domenico Plantone

Lancet Neurol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Psychometric properties of the PHQ-9 depression scale in people with multiple sclerosis: A systematic review.
Sarah Patrick, Peter Connick

PLoS One· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regional variation in the incidence rate and sex ratio of multiple sclerosis in Scotland 2010-2017: findings from the Scottish Multiple Sclerosis Register.
Patrick K A Kearns, Martin Paton, Martin O'Neill, Chrissie Waters, Shuna Colville, Peter Connick

J Neurol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A single systemic inflammatory insult causes acute motor deficits and accelerates disease progression in a mouse model of human tauopathy.
Megan Torvell, David W Hampton, Peter Connick, Alasdair M J MacLullich, Colm Cunningham

Alzheimers Dement (N Y)· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis.
Peter Connick, Floriana De Angelis, Richard A Parker, Domenico Plantone, Anisha Doshi

BMJ Open· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis